Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases

Journal of the Neurological Sciences

Volumn 158, Issue 1, 1998, Pages 24-29

  Gu, M ^a   Owen, A D ^b   Toffa, S E K ^b   Cooper, J M ^a   Dexter, D T ^b   Jenner, P ^b   Marsden, C D ^c   Schapira, A H V ^a,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Neurodeg Disease Research Centre   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Free radicals; Iron; Lewy body; Mitochondria; Parkinson's disease

Indexed keywords

BETA CARBOLINE DERIVATIVE; GLUTATHIONE; IRON; ISOQUINOLINE DERIVATIVE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; MITOCHONDRIAL RESPIRATION; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0032507983     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00095-1     Document Type: Article

References (37)

1. Balazs L., Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res. 19:1994;1131-1137.
2. Chagnon P., Bétard C., Robitaille Y.et al. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Mol Neurosci. 6:1995;711-715.
3. Cooper J.M., Wischik C., Schapira A.H.V. Mitochondrial function in Alzheimer's disease. Lancet. 341:1993;969-970.
4. Dagani F., Ferrari R., Anderson J.J.et al. L-Dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria. Mov Disord. 6:1991;315-319.
5. Dexter D.T., Wells F.R., Lees A.J.et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem. 52:1989;1830-1836.
6. Dexter D.T., Carayon A., Vidailhet M.et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem. 55:1990;16-20.
7. Dexter D.T., Carayon A., Javoy-Agid F.et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
8. Dexter D.T., Sian J., Rose S.et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 35:1994;38-44.
9. Gu M., Cooper J.M., Gash M.et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 39:1996;385-389.
10. Hartley A., Cooper J.M., Schapira A.H.V. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res. 627:1993;349-353.
11. Hensley K., Hall N., Sabramaniam R.et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers for protein oxidation. J Neurochem. 65:1995;2146-2156.
12. Hirsch E.C., Brandel J.-P., Galle P.et al. Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem. 56:1991;446-451.
13. Hughes A.J., Daniel S.E., Blankson S.et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 50:1993;140-148.
14. Janetzky B., Hauck S., Youdim M.B.H.et al. Unaltered aconitase activity but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett. 169:1994;126-128.
15. Jenner P., Schapira A.H.V., Marsden C.D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
16. Kish S.J., Bergeron C., Rajput A.et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem. 59:1992;776-779.
17. Lovell M.A., Ehmann W.D., Butler S.M.et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain of Alzheimer's disease. Neurology. 45:1995;1594-1601.
18. Lowry O.H., Rosebrough N.J., Farr A.L.et al. Protein measurement with the folin reagent. J Biol Chem. 193:1951;265-275.
19. Mann V.M., Cooper J.M., Krige D.et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain. 115:1992;333-342.
20. Mann V.M., Cooper J.M., Daniel S.E.et al. Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol. 36:1994;876-881.
21. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 36:1994;747-751.
22. Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J Neurochem. 66:1996;1174-1181.
23. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem. 3:1994;2179-2184.
24. Pardo B., Mena M.A., de Yebenes J.G. L-Dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma N869 cells. J Neurochem. 64:1995;576-582.
25. Parker W.D., Parks J., Filley C.M.et al. Electron transport chain defects in Alzheimer's disease. Neurology. 44:1994;1090-1096.
26. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett. 33:1982;305-310.
27. Polymeropoulos M.H., Lavedan C., Leroy E.et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
28. Przedborski S., Jackson-Lewis V., Muthane U.et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol. 34:1993;715-723.
29. Reichmann H., Flörke S., Hebenstreit G.et al. Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease. J Neurol. 240:1993;377-380.
30. Riederer P., Sofic E., Rausch W.D.et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem. 52:1989;515-520.
31. Saggu H., Cooksey J., Dexter D.et al. A selective increase in particulate superoxide dismutase activity in Parkinson's substantia nigra. J Neurochem. 53:1989;692-697.
32. Schapira A.H. V, Cooper J.M., Dexter D.et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 54:1990;823-827.
33. 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 55:1990;2142-2145.
34. Sian J., Dexter D.T., Lees A.J.et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 36:1994;348-355.
35. Sofic E., Lange K.W., Jellinger K.et al. Reduced and oxidised glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett. 142:1992;128-130.
36. Stein A.F., Dills R.L., Klaassen C.D. High-performance liquid chromatographic analysis of glutathione and its thiol and disulfide degradation products. J Chromatogr. 381:1986;359-370.
37. Thomas P.K., Cooper J.M., King R.H.M.et al. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. J Anat. 183:1993;451-461.